

Ravoxertinib

Catalog No: tcsc3704



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

1453848-26-4

Formula:

$C_{21}H_{18}ClFN_6O_2$

Pathway:

Stem Cell/Wnt;MAPK/ERK Pathway

Target:

ERK;ERK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 35 mg/mL (79.39 mM)

Alternative Names:

GDC-0994

Observed Molecular Weight:

440.86


Product Description

Ravoxertinib (GDC-0994) is an orally bioavailable **ERK** kinase inhibitor with an **IC₅₀** of 6.1 nM and 3.1 nM for **ERK1** and **ERK2**, respectively.

IC50 & Target: IC50: 6.1 nM (ERK1), 3.1 nM (ERK2), 12 nM (p90RSK)^[1]

In Vitro: Ravoxertinib (GDC-0994) also inhibits p90RSK with IC₅₀ of 12 nM^[1]. Ravoxertinib (GDC-0994) is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively^[2].

In Vivo: In CD-1 mice, a 10 mg/kg oral dose of Ravoxertinib (GDC-0994) is sufficient to achieve the desired target coverage for at least 8 h^[1]. Daily, oral dosing of Ravoxertinib results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!